Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4UHB5)

• Drug Name: Nitrobenzaldehyde Drug Info
• Synonyms: Benzaldehyde, 4-nitro-; 4-Nitrobenzaldehyde; Benzaldehyde, p-nitro-; NX859P8MB0; p-Formylnitrobenzene; p-Nitrobenzaldehyde; p-nitro benzaldehyde; p-nitro-benzaldehyde; para-nitrobenzaldehyde; paranitrobenzaldehyde; 4-FORMYLNITROBENZENE; 4-Nitro-benzaldehyde; 4-Nitrobenzaldehydde; 4-Nitrobenzaldehyde, 99%; 4-nitro benzaldehyde; 4-nitrobenz aldehyde; 4-nitrobenzaldehyd; 4-nitrobenzaldehyde; 4-nitrobenzaldhyde; 555-16-8; AI3-52475; BXRFQSNOROATLV-UHFFFAOYSA-N; CCRIS 1675; CHEBI:66926; EINECS 209-084-5; MFCD00007346; NSC 6103; UNII-NX859P8MB0; XXH
• Cross-matching ID:
  PubChem CID: 541
  ChEBI ID: CHEBI:66926
  CAS Number: CAS 555-16-8
  TTD Drug ID: DM4UHB5
  INTEDE Drug ID: DR0014

Molecule-Related Drug Atlas

Drug(s) Metabolized By NADPH-dependent carbonyl reductase 3 (CBR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[2]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[6]
Trastuzumab emtansine	DMU1LXS	HER2-positive breast cancer	2C60-2C65	Phase 2	[7]
Phenanthrene-9,10-dione	DMG8KS9	Discovery agent	N.A.	Investigative	[8]
1H-Indole-2,3-dione	DMOZ91H	Discovery agent	N.A.	Investigative	[9]
ACMC-209cv7	DMQCSFB	N. A.	N. A.	Investigative	[2]

Drug(s) Metabolized By Aldo-keto reductase 1A1 (AKR1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[10]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[11]
NADH	DM5NM6E	Parkinson disease	8A00.0	Approved	[12]
2,3-dihydroxypropanal	DMOWNB4	Discovery agent	N.A.	Investigative	[1]
D-glucuronate	DM1YBTC	N. A.	N. A.	Investigative	[1]
BRN-0471734	DMZMWVX	N. A.	N. A.	Investigative	[1]

Drug(s) Metabolized By Farnesol dehydrogenase (AKR1B15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[13]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[13]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[13]

Drug(s) Affected By Aldo-keto reductase family 1 member A1 (AKR1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[14]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[19]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[20]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[16]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[14]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]

Drug(s) Affected By Aldo-keto reductase family 1 member B1 (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[22]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[23]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[24]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[27]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[18]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[27]

Drug(s) Affected By Dehydrogenase/reductase SDR family member 7 (DHRS7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[22]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[30]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[31]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[32]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Aldo-keto reductase 1A1 (AKR1A1)	DED2FW3	AK1A1_HUMAN	Substrate	[1]
NADPH-dependent carbonyl reductase 3 (CBR3)	DEIVKZ8	CBR3_HUMAN	Substrate	[2]
Farnesol dehydrogenase (AKR1B15)	DER0XCH	AK1BF_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member A1 (AKR1A1)	OTZT9NOW	AK1A1_HUMAN	Biotransformations	[4]
Aldo-keto reductase family 1 member B1 (AKR1B1)	OTRX72TH	ALDR_HUMAN	Biotransformations	[4]
Dehydrogenase/reductase SDR family member 7 (DHRS7)	OTV729DT	DHRS7_HUMAN	Biotransformations	[5]

References

• [1] The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
• [2] Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
• [3] Functional expression of novel human and murine AKR1B genes. Chem Biol Interact. 2011 May 30;191(1-3):177-84.
• [4] Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J. 1999 Oct 15;343 Pt 2(Pt 2):487-504.
• [5] Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. Chem Biol Interact. 2014 Jan 25;207:52-7. doi: 10.1016/j.cbi.2013.11.003. Epub 2013 Nov 16.
• [6] Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
• [7] The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
• [8] Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
• [9] Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis. Chem Biol Interact. 2009 Mar 16;178(1-3):234-41.
• [10] Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
• [11] Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
• [12] Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
• [13] Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
• [14] Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro. Drug Metab Dispos. 2008 Jun;36(6):991-4. doi: 10.1124/dmd.108.020388. Epub 2008 Mar 5.
• [15] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [16] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [17] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [18] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [19] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [20] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [21] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [22] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [23] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [24] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [25] Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. Chem Biol Interact. 2009 Mar 16;178(1-3):250-8. doi: 10.1016/j.cbi.2008.11.007. Epub 2008 Nov 18.
• [26] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [27] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [28] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [29] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [30] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [31] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [32] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [33] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.